Title for MeetingAbstracts

Alphabetical listing of titles

• Improved Presentations of Envelope Immunogens Derived From Subtypes B and C HIV-1 Provide Increased Breadth of Neutralizing Antibody Responses.
• Improved prognosis of HIV infection in newborns and children by PCR amplification of viral RNA.
• Improved proliferative function of peripheral blood mononuclear leukocytes (PBML) of HIV1-infected patients after initiation of therapeutic HIV protease inhibition.
• Improved quality improvement ratio: an expanded methodology to analyze changes in utilization rates.
• Improved Quality of Antimicrobial Susceptibility Testing Data for Streptococcus pneumoniae Using World Health Organization's External Quality Assurance Program.
• Improved quantification of plasma RNA for non-B HIV-1 subtypes using the HIV-1 Monitor with additional primers.
• Improved Recovery of Vancomycin-resistant Enterococci (VRE) from the Hospital Environment Using Broth Enrichment.
• Improved self reporting of HIV risk behaviours through self-administered forms for rural, low literacy populations.
• Improved sensitivity of Mycobacterial growth indicator tubes (MGIT) with osmotic stabilization of the media.
• Improved seroconversion sensitivity of HIV-1 specific antibodies with a new HIV-1/HIV-2 microplate ELISA.
• Improved skills development for persons living with HIV/AIDS and service providers in Mexico and Canada.
• Improved specificity for serotyping HIV-1 in Uganda by use of V3 and gp41 env peptides.
• Improved specificity of an HIV-1/2 recombinant strip immunoblot (SIA) compared with HIV-1 Western blot.
• Improved STD treatment significantly reduces prevalence of syphilis and symptomatic urethritis in rural Tanzania.
• Improved surgical technique for implantation of the intraocular sustained-release ganciclovir implant reduce postoperative complications in patients with AIDS and CMV-retinitis.
• Improved survival among men and women on triple antiretroviral therapy.
• Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase, SQV) plus HIVID (zalcitabine, ddC).
• Improved survival for persons with AIDS in San Francisco.
• Improved survival in AIDS patients with opportunistic infections.
• Improved survival in disseminated MAC treated with clarithromycin containing regimens.
• Improved survival in HIV/AIDS patients treated with aggressive combination antiretroviral therapy.
• Improved survival of AIDS patients in Dallas, Texas after 1986.
• Improved survival time after diagnosis with AIDS among adults in New York City (NYC), 1980-1994.
• Improved survival time and CD4 slope associated with recent advances in HIV antiretroviral therapy.
• Improved survival with correction of anemia in HIV disease.
• Improved survival, earlier presentation, changed service use and cost of care for AIDS patients in London, 1982-1989.
• Improved survival, from time of AIDS diagnosis, for intravenous drug users diagnosed in 1987.
• Improved targeting of HIV/AIDS interventions through analysis based on phenomenological and interactionist theories: The Belize case study.
• Improved Therapy of Pneumococcal Pneumonia by the Combination of a Nitric Oxide Donor (Sodium Nitroprusside) and Ceftriaxone.
• Improved tolerability and adherence with enteric coated didanosine capsules (VidexEC) versus buffered tablets (Videx).